• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Imperative Care Appoints Three to Its Board of Directors

    8/20/21 8:00:00 AM ET
    $COO
    $OM
    $SGHT
    Ophthalmic Goods
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $COO alert in real time by email

    Holly Sheffield, Medical Technology Executive and Investment Banker

    Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader

    James Rogers, Public and Private Medical Technology Investor

    Imperative Care, Inc. today announced three appointments to the company's Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers.

    "We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts," said Fred Khosravi, Chairman and CEO of Imperative Care. "Having these high-caliber professionals join our Board speaks to the potential of our programs in bringing more innovative technologies to market faster and meeting patients' needs in the fields of stroke and peripheral vascular disease."

    After a distinguished career of more than 20 years in investment banking, Holly Sheffield joined CooperCompanies (NYSE:COO) as Executive Vice President, Chief Strategy Officer in June of 2018. Last year, Holly was named President of CooperSurgical, one of Cooper Companies' two business units. CooperSurgical is focused on advancing the standard of healthcare for women and families worldwide. Prior to this, she was Managing Director and Global Head of Medical Technology Investment Banking at UBS Securities. She also worked at Donaldson, Lufkin & Jenrette, where she started in 1997, until its acquisition by Credit Suisse, where she stayed as a Managing Director until 2009. Holly is a graduate of Cornell University and obtained her MBA from Columbia University.

    Before transitioning to the world of venture capital, Hank Plain began his highly successful career in the pharmaceutical and medical device industries more than 40 years ago. As the CEO of Perclose, he led the company through a successful IPO and acquisition by Abbott Laboratories. Following this, he co-founded eight medical device companies as part of his work at The Foundry medical device incubator. In addition to currently serving as Partner of Morgenthaler Ventures and Lightstone Ventures, he is on numerous Boards including Nuvaira, Moximed, Earlens and Setpoint. He also serves as Chairman of the Board of Trustees for the Naval Postgraduate School Foundation and on the Future Citizens Foundation/First Tee Board. He is a graduate of the University of Missouri with a B.S. in Finance.

    James Rogers is an Analyst at D1 Capital Partners, the lead investor in Imperative Care's $260 million Series D financing announced last month. Since D1 launched in July 2018, James has led over a dozen private financings, including investments in innovative medical technology companies such as Auris Health, Outset Medical (NASDAQ:OM), and Sight Sciences (NASDAQ:SGHT). Previously, he was a Principal at Valinor Management and an Analyst at The Blackstone Group. James graduated from the University of Virginia with a B.S. in Commerce and a B.A. in History as a Jefferson Scholar and an Echols Scholar.

    "Imperative Care's intentional mission to impact the continuum of stroke care and vascular thrombectomy, elevating innovations in order to make more care available to more patients globally, requires a Board with a long-term horizon and broad expertise. Holly, Hank and James will further strengthen the tremendous prowess of the existing Imperative Care Board, to help achieve this important mission. We are delighted to have them on the team," said John Hamre, Ph.D., Chairman of the Nominating and Governance Committee of the Imperative Care's Board of Directors.

    About Imperative Care, Inc.

    Imperative Care is a vascular technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke. The company has two 510(k) cleared product platforms, as well as an expansive stroke technology development pipeline. In addition, Imperative Care's wholly owned subsidiary, Truvic Medical, Inc., is developing solutions for the treatment of peripheral vascular disease. Imperative Care and Truvic Medical are based in Campbell, Calif.

    For more information, visit www.imperativecare.com and www.truvic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005043/en/

    Get the next $COO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO
    $OM
    $SGHT

    CompanyDatePrice TargetRatingAnalyst
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    The Cooper Companies Inc.
    $COO
    11/13/2025$72.00Overweight → Equal Weight
    Wells Fargo
    The Cooper Companies Inc.
    $COO
    10/13/2025$85.00Overweight
    Barclays
    The Cooper Companies Inc.
    $COO
    10/1/2025$64.00Sell
    Goldman
    The Cooper Companies Inc.
    $COO
    8/28/2025$72.00Buy → Neutral
    Citigroup
    Sight Sciences Inc.
    $SGHT
    8/8/2025$5.00Hold → Buy
    Lake Street
    The Cooper Companies Inc.
    $COO
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    The Cooper Companies Inc.
    $COO
    6/17/2025$94.00Hold → Buy
    Needham
    More analyst ratings

    $COO
    $OM
    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Cooper downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cooper from Overweight to Equal Weight and set a new price target of $72.00

    11/13/25 8:26:09 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Barclays initiated coverage on Cooper with a new price target

    Barclays initiated coverage of Cooper with a rating of Overweight and set a new price target of $85.00

    10/13/25 8:52:29 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    $OM
    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperVision Partners with Canadian Sprint Canoe Athlete Nikita Ciudin on His Journey to Compete on the World Stage

    RICHMOND HILL, ON, Jan. 7, 2026 /CNW/ - CooperVision Canada is proud to announce its sponsorship and partnership with Nikita Ciudin, an elite sprint canoe paddler and dedicated MiSight® 1 day contact lens wearer, as he strives toward representing Team Canada at the world's biggest sporting event. Nikita's story is one of vision—both literal and figurative. Diagnosed with myopia at a young age, Nikita has relied on MiSight® 1 day* contact lenses to slow the worsening of his myopia1 while pursuing his passion for competitive paddling. Today, he is a rising star in Canadian sprin

    1/7/26 5:16:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Chair & CEO Leslie Trigg will present at the 44th annual J.P. Morgan Healthcare conference on Wednesday, January 14, 2026, at 4:30 p.m. Pacific time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc.Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kin

    1/5/26 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CooperCompanies to Present at the J.P. Morgan Healthcare Conference

    SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Al White, President and CEO, will represent the Company in a session scheduled to begin at 5:15pm ET. A live and archived webcast of the event, where applicable, will be available on the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. Coop

    12/29/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    $OM
    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucchese Cynthia L bought $149,963 worth of shares (1,784 units at $84.06), increasing direct ownership by 23% to 9,445 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/23/25 4:08:36 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Rivas Maria bought $82,130 worth of shares (1,000 units at $82.13) (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/19/25 4:18:51 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Encrantz Staffan bought $115,963 worth of shares (13,958 units at $8.31), increasing direct ownership by 1% to 1,391,922 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    12/18/25 6:10:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $COO
    $OM
    $SGHT
    SEC Filings

    View All

    SEC Form 144 filed by Outset Medical Inc.

    144 - Outset Medical, Inc. (0001484612) (Subject)

    1/7/26 6:07:53 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by Sight Sciences Inc.

    144 - Sight Sciences, Inc. (0001531177) (Subject)

    1/5/26 4:12:13 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Sight Sciences Inc.

    144 - Sight Sciences, Inc. (0001531177) (Subject)

    1/2/26 4:13:46 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $COO
    $OM
    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP Operations R&D & Service Nash Marc sold $461 worth of shares (108 units at $4.27), decreasing direct ownership by 0.22% to 48,160 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    1/8/26 5:10:33 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    General Counsel Brottem John L. sold $956 worth of shares (224 units at $4.27), decreasing direct ownership by 0.48% to 46,271 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    1/8/26 5:09:01 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chair and CEO Trigg Leslie sold $7,665 worth of shares (1,795 units at $4.27), decreasing direct ownership by 1% to 119,617 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    1/8/26 5:05:21 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $COO
    $OM
    $SGHT
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

    SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically.Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025 GAAP diluted EPS of $1.87, down 4%.Fourth quarter 2025 non-GAAP diluted EPS of $1.15, up 11%. Fiscal 2025 non-GAAP diluted EPS of $4.13, up 12%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We closed fis

    12/4/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2025, and raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated third quarter 2025 total revenue of $19.9 million, a decrease of 1% compared to the same period in the prior year. The Company's Surgical Glaucoma revenue increased

    11/6/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025

    SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2700541. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience l

    11/4/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    $OM
    $SGHT
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    Browning West Delivers Letter to The Cooper Companies Board of Directors

    Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance Current Corporate Structure Obscures Value of Both CooperVision and CooperSurgical; Refocus as a Pure Play Vision Care Company Under a Refreshed Board May Lead to More Than a Doubling of Cooper's Stock Price Urges Cooper's Board to Appoint Browning West's Highly Skilled Director Candidates Who Will Improve the Company's Operating Plans Including Capital Allocation, Overhaul Management Incentives, and Evaluate Strategic Alternatives for CooperSurgical LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Browning West, LP ("Browning West", "us", or "we"), an investment

    11/19/25 8:45:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $COO
    $OM
    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    11/14/24 11:57:36 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:53:46 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:26:01 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care